... Happy new year, hot bunnies!

The whole thing will be held as cash and $INOD (+0,73%) when the price is right :)

LG

Hello my dears,

I wish you all a happy and successful New Year.

Looking back, I have picked out the TOP stocks from the NASDAQ Composite.

The question arises as to whether any of you have had these companies in your portfolio or on your radar.

I often see here that the focus is mostly on companies from the S&P. Which I also think makes sense.

Just like Buffet "Only buy what you understand" BURGGRABEN

Risk arises when you don't know what you're doing.

However, if we pursue a core-satellite strategy, we should also take a look at these companies as small satellite positions.

What strikes me immediately about the top nine is that none of these companies generates a P/E ratio.

Personally, I always find it a little difficult to invest here, unless a profit is to be expected.

We also often look at the market capitalization, which is not very high for some of these companies.

Furthermore, some companies are followed by no or only a few analysts. There are then no estimates, which often makes analysis difficult.

In the case of biotech companies, we are often not involved in the topic at all.

As small investors, we are naturally at a disadvantage here in all respects.

We should therefore concentrate on the companies that we can assess.

I have also noticed that some companies can even have a very low P/E ratio.

Such as FreightCar America $RAIL (-0,51%) with a P/E ratio of 12.59 which falls to 10.88.

A quick glance shows me that the company has become profitable again. Which is perhaps responsible for the price increase. A detailed analysis might be worthwhile here. @BamBamInvest ?

The situation is similar at Citius Pharmceuticals $CTXR is making its first profits and the P/E ratio is even falling to 0.22. According to Eulerpool, I could see that they want to generate a profit of 50mn in 2026, which will be increased to 189mn next year. The EbiT margin will then be 50% in 2026 and will continue to increase. (Maybe put it on the watch. ( ATTENTION PENNYSTOCK highly speculative)

At Kingstone Companies $KINS the chart looks like a flagpole. Nevertheless, the P/E ratio of 10.04 is not too expensive for an insurance company that has just become profitable.

Sensus Healtcare $SRTS (+0,38%) has a P/E ratio of 12.58, which falls to 8.15 due to further growth. The company has just returned to the 200-day line, perhaps a good time to enter the market.

Home - Sensus Healthcare

I think this is a small selection of companies which, despite a remarkable performance in 2024, still have an acceptable P/E ratio.

It might be worth analyzing other companies from the overview in more detail.

I myself was briefly invested in Willis Lease $WLFC (+1,22%) until I was thwarted by a stop loss. Volatility is to be expected with low market capitalization.

I am still invested in $APP (-0,02%) AppLovin and $INOD (+0,73%) Inodata.

As I have seen, some are still invested in $HOOD (+0,18%) invested.

I would be interested to know if you are invested in companies from the overview and what do you think about investing in rather small, often unknown companies from the NASDAQ Composite. Do you see too much risk here, or rather potential to push the portfolio?

Please do not regard this as an investment recommendation. Rather, let's discuss it. I look forward to your comments.

Which shares do you have on your watchlist for 2025? 🚀

I'll start right away: $LIN (+1,27%)
$8001 (-2,91%)
$ZTS (+0,03%)
$FANG (+0,57%)
$MUM (+0,28%)
$HOOD (+0,18%)
$INOD (+0,73%)
$UBER (+0,64%)
$MDLZ (-0,22%)

$INOD (+0,73%)

As previously reported, Wedbush initiated coverage on Innodata ( INOD ) with an Outperform rating and a $48 price target . The digital services and data transformation company is currently the preferred partner in data quality, scalability and agility, having signed contracts with five of the Magnificent 7, with two more deals expected later this year, the analyst tells investors. The company believes that Innodata's decades of experience in data annotation and AI will make it a "leader in this evolving space," the analyst added.

https://finance.yahoo.com/news/wedbush-starts-under-radar-ai-115045415.html

Innodata share rises to all-time high and reaches USD 49.84. $INOD (+0,73%)

Looking ahead, the company is focused on generative AI and data science services for large technology companies and plans to expand relationships with seven major customers and increase federal government engagement.

Innodata Inc (INOD) has reached a notable milestone, with its share price rising to an all-time high of $49.84. The company, now valued at $1.39 billion, has shown impressive revenue growth of 72% over the last twelve months, with InvestingPro data showing a robust financial health score of "OUTSTANDING." This significant performance reflects a staggering 445.29% increase over the past year and marks a period of exceptional growth for the company. Investors have shown increasing confidence in Innodata's business model and future prospects, as evidenced by the impressive rise in the share price to this record level. The company's strategic initiatives and market performance have clearly resonated with the market, culminating in this all-time high. According to InvestingPro's analysis, while the stock appears overvalued at current levels, subscribers have access to 21 additional investment insights, including detailed valuation metrics and growth forecasts in the comprehensive Pro Research Report.

In other recent news, Innodata reported record third quarter revenue of $52 million, a significant increase of 136% year-over-year. This substantial growth was largely due to a $30.6 million revenue contribution from a single Big Tech customer and expanded federal government engagements. The company's adjusted EBITDA reached $13.9 million, representing 27% of revenue. Innodata also raised its full-year 2024 revenue guidance to $52 million to $55 million, representing expected growth of 88% to 92%.

In addition to these financial highlights, Innodata increased its cash reserves to $26.4 million, $10 million more than the previous quarter. The company also received SEC approval for a $50 million securities offering, although there are no immediate plans to raise funds. These recent developments reflect robust business momentum for Innodata, with strong expectations for continued growth in the final quarter and in the coming year.

https://www.investing.com/news/company-news/innodata-stock-soars-to-alltime-high-hits-4984-93CH-3761699

INODATA (ONOD) SAYS IT IS NOW READY TO SUPPORT FOUR OF THE FIVE LARGEST GLOBAL TECHNOLOGY COMPANIES IN THE DEVELOPMENT OF GENERATIVE KI!

Innodata (ISIN: US4576422053)

Innodata is a company that provides specialized data solutions and AI-powered services. It supports companies in structuring, analyzing and refining large amounts of data and develops technologies to make information from complex content efficiently usable. The company was founded in 1988. The IPO took place in 1993.

With a focus on the IT, healthcare and financial services sectors, Innodata optimizes business processes for its customers and helps them make well-founded decisions based on data analysis. As the demand for data-driven strategies and AI-supported decision-making is becoming increasingly crucial for competitiveness, Innodata has enormous growth potential.

On November 7, 2024, Innodata delivered its figures for the past Q3 2024, with revenue of USD 52 million up a whopping 136% on the previous year. The net profit of USD 0.51 also exploded compared to the previous year's result of USD 0.01. As a result, management raised its forecast for the full year 2024 to revenue growth of between 88% and 92% compared to the previous year.

The chart clearly shows the significance of the latest quarterly report for the company. The share price rose by almost 76%. The trading volume was at a record level. The gap-up can be interpreted as a technical indication of how much appetite major investors have for Innodata shares.

Conclusion: Innodata is a data analytics company that offers specialized solutions and AI services. In Q3 2024, it achieved impressive results with revenue growth of 136% and raised its full-year guidance. The strong quarterly figures led to a share price increase of almost 76%, which shows that institutional investors are very interested in the stock.

https://mobile.aktien-mag.de/blog/welche-3-aktien-lieferten-die-starksten-quartalsberichte/id-130650

$INOD (+0,73%)

Can anyone tell me anything about the share?

Somehow I don't read anything about it.